Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.

Literature DB >> 34086482

Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.

Paul B Chapman¹.

Abstract

Entities: Chemical

Mesh：

Substances：
Antigens, Neoplasm

Year: 2021 PMID： 34086482 PMCID： PMC8376378 DOI： 10.1200/JCO.21.01012

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 50.717

× No keyword cloud information.

23 in total

1. Immunity to methylcholanthrene-induced sarcomas.

Authors: R T PREHN; J M MAIN
Journal: J Natl Cancer Inst Date: 1957-06 Impact factor: 13.506

2. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors: Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531

3. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Authors: Shari Pilon-Thomas; Lisa Kuhn; Sabine Ellwanger; William Janssen; Erica Royster; Suroosh Marzban; Ragini Kudchadkar; Jonathan Zager; Geoffrey Gibney; Vernon K Sondak; Jeffrey Weber; James J Mulé; Amod A Sarnaik
Journal: J Immunother Date: 2012-10 Impact factor: 4.456

4. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors: M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal: J Immunother Date: 2001 Jul-Aug Impact factor: 4.456

5. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors: S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal: N Engl J Med Date: 1988-12-22 Impact factor: 91.245

6. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal: Science Date: 2002-09-19 Impact factor: 47.728

7. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

Authors: E De Plaen; C Lurquin; A Van Pel; B Mariamé; J P Szikora; T Wölfel; C Sibille; P Chomez; T Boon
Journal: Proc Natl Acad Sci U S A Date: 1988-04 Impact factor: 11.205

Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.

1. Immunity to methylcholanthrene-induced sarcomas.

2. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

3. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

4. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

5. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

6. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

7. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

Review 8. Interleukin-2: clinical applications.

9. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.

10. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Review 1. Harnessing cytokines and chemokines for cancer therapy.

2. GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma.